Study reveals potential for PD-1 treatments to strengthen cancer treatment and block overactive immune responses in autoimmune diseases.

A study by NYU Langone Health's Perlmutter Cancer Center and the University of Oxford reveals insights into PD-1, an immune cell surface receptor. These findings suggest that treatments that restrict PD-1 action can be strengthened for cancer treatment, while stimulating its action may help block an overactive immune response in autoimmune diseases. The study, published in Science Immunology, focuses on the body's immune system and its use of checkpoints to spare normal cells from immune attack.

March 08, 2024
4 Articles